Head of EIP’s Düsseldorf office, Christof Höhne, outlines the implications of Germany’s compulsory licensing in an article for the latest issue of the European Pharmaceutical Review. Two recent, high-profile pharmaceutical cases which have set the course for the future of German IP law are analysed by Christof, who highlights the advantages and disadvantages faced by both parties in a licensing negotiation.
The article can be read on the European Pharmaceutical Review website here.